Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. (Q48031825)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 June 2006

Language	Label	Description	Also known as
English	Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.	scientific article published on 12 June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Plasmodium falciparum

0 references

6

object named as

Liwang Cui

1 reference

Europe PubMed Central

7 February 2018

author name string

Jun Miao

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Xun Li

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Zhongxiang Liu

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Caifang Xue

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Hermann Bujard

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

language of work or name

0 references

publication date

12 June 2006

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

24

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

37-39

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

6187-6198

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

The economic and social burden of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Towards a blood-stage vaccine for malaria: are we following all the leads?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Integral membrane protein located in the apical complex of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

The disulfide bond structure of Plasmodium apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Crystal structure of the malaria vaccine candidate apical membrane antigen 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Functional analysis of Plasmodium falciparum apical membrane antigen 1 utilizing interspecies domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Specificity of the protective antibody response to apical membrane antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Immune effector mechanisms in malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

The complexity of protective immunity against liver-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

DNA prime-protein boost immunization in monkeys: efficacy of a novel construct containing functional domains of Plasmodium cynomolgi CS and TRAP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Prime-boost strategies for malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Human malaria parasites in continuous culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Plasmodium falciparum: differential display analysis of gene expression during gametocytogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Characterization of PfPuf2, member of the Puf family RNA-binding proteins from the malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

Antibody-independent immunity to reinfection malaria in B-cell-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.099

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.05.099

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/16806600

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48031825&oldid=1382092979"